Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : The Trump Presidency -- Ignore unavailable to you. Want to Upgrade?

To: Wharf Rat who wrote (164526)	5/18/2020 10:58:15 AM
From: i-node	Read Replies (1) \| Respond to of 357216

>> Some studies have been stopped because of heart problems, so the drug is life-taking. HCQ is not properly given to patients with cardiac issues or certain diseases of the retina. The Brazil study, and one other I know of, were stopped because they overdosed the patients with HCQ. It is a powerful drug and has a long half-life. You cannot put patients on a loading dosage then leave them on it. When I read the Brazil study even a lowly accountant like me could see they were killing the patients on first reading. Finally, others came out and said it. But not the news media, oh no.